DAS181

Phase 3Small molecule

AAnsun Biopharma, Inc.

DAS181 is one of 71 small molecule programs targeting Bronchiectasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiectasisActive, not recruiting

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

Lower Respiratory Tract InfectionRecruiting

BronchiectasisPhase 1

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

InfluenzaPhase 1

Active, not recruiting

Lower Respiratory Tract InfectionPhase 3

Recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

DAS181

AAnsun Biopharma, Inc.

Phase 3

4 2

Spikevax

Moderna

Preclinical

21 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Tricor

JJagotec

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Benadryl

PParkedale

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Selenium

SSWOG Cancer Research Network

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Lower Respiratory Tract Infection

NCT03808922

Clinical

Trials by Indication[1]

Influenza5 trials

DAS181 in Patients With Parainfluenza

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01441024

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Completed·AAnsun Biopharma, Inc.·Phase 2·NCT01644877·111 enrolled

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Completed·AAnsun Biopharma, Inc.·Phase 2·NCT01037205·264 enrolled

Show 2 more trials

Influenza Antiviral DAS-181-F04 in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01651494·9 enrolled

Influenza Antiviral DAS181-F03

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01173224·18 enrolled

COVID-194 trials

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

Unknown status·QQassim University··NCT04460547·200 enrolled

DAS181 for STOP COVID-19

Withdrawn·AAnsun Biopharma, Inc.·Phase 2/3·NCT04354389

DAS181 for Severe COVID-19: Compassionate Use

Completed·RRenmin Hospital of Wuhan University·N/A·NCT04324489·4 enrolled

Show 1 more trial

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

Unknown status·AAnsun Biopharma, Inc.·Phase 2·NCT04298060·280 enrolled

Single Dose2 trials

DAS181 Single Dose Escalation Study in Healthy Adults

Completed·AAnsun Biopharma, Inc.·Phase 1·NCT00876161·45 enrolled

Single Dose Escalating Study of DAS181 in Adults

Completed·AAnsun Biopharma, Inc.·Phase 1·NCT00527865·36 enrolled

Bronchiectasis1 trial

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

Completed·AAnsun Biopharma, Inc.·Phase 1·NCT01113034·11 enrolled

Lower Respiratory Tract Infection1 trial

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

Recruiting·AAnsun Biopharma, Inc.·Phase 3·NCT03808922·274 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for DAS181. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DAS181 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DAS181. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ansun Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAnsun Biopharma, Inc.

DAS181

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Influenza5 trials

COVID-194 trials

Single Dose2 trials

Bronchiectasis1 trial

Lower Respiratory Tract Infection1 trial

References

Drug Info

Quick Facts

Related News